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Abstract: Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter located in the mammalian central nervous 
system, which binds to GABAA and GABAB receptors to mediate its neurological effects. In addition to its role in the CNS, 
an increasing number of publications have suggested that GABA might also play a role in the regulation of renal function. 
All three enzymes associated with GABA metabolism; glutamic acid decarboxylase, GABA -oxoglutarate transaminase 
(GABA-T) and succinic semialdehyde dehydrogenase (SSADH) have been localised to the kidney providing the 
necessary machinery for localised GABA synthesis and metabolism. Moreover GABA receptors have been localised to 
both tubular and vascular structures in the kidney, and GABA is excreted in urine (~3 μM) in humans. Despite the 
collective evidence describing the presence of a GABA system in the kidney, the precise function of such a system 
requires further clarification. Here we provide an overview of the current renal GABA literature and provide novel data 
that indicates GABA can act at contractile pericyte cells located along vasa recta capillaries in the renal medulla to 
potentially regulate medullary blood flow. 
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INTRODUCTION 
Gamma-aminobutyric acid (GABA) is an established 
inhibitory neurotransmitter, most commonly associated 
with having a functional role in the mammalian central 
nervous system (CNS). This endogenous amino acid is 
expressed in the vertebrate CNS [1], peripheral 
nervous system [2], and in several non-neural tissues 
[3]. In the CNS, GABA acts at GABAA receptors 
(GABAAR) to exert fast inhibitory action and at GABAB 
receptors (GABAAR) to mediate slower inhibitory 
transmission. GABAARs are ligand-gated chloride 
channels, which belong to a superfamily of 
heteropentameric ligand-gated ion channel receptors 
[4]. GABAAR subunits are encoded by 19 different 
genes, which are grouped into eight subclasses 
determined by their sequence homology (1–6, 1–3, 
1–3, , , , , 1–3) [5]. GABABRs are metabotropic 
receptors belonging to the G protein-coupled receptor 
superfamily (GPCRs) [6]. GABABRs principally consist 
of GABAB1 and GABAB2 subunits [7] and an auxiliary K
+
 
channel tetramerisation domain (KCTD) subunit [8, 9]. 
The GABAB1 subunit has two isoforms, GABAB1a and 
GABAB1b, which combined with GABAB2 to form 
functional GABABRs. 
GABA is synthesised in vivo by the metabolic GABA 
shunt pathway, which acts to both synthesise and  
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conserve GABA in a closed-loop system [10]. GABA 
synthesis occurs following the decarboxylation of 
glutamic acid by glutamate decarboxylase (GAD) [1], 
whilst conservation of GABA is achieved by GABA-T-
mediated transamination of GABA to succinic 
semialdehyde (SSA), which is subsequently utilised to 
regenerate glutamic acid [10].  
Whilst much of our knowledge regarding the 
function of GABA has historically originated from 
studies performed in the CNS, GABA and its metabolic 
enzymes have since been detected in numerous 
peripheral tissues, including the liver [11], spleen [12], 
oviduct [13, 14], testis [15], pancreas [16, 17], adrenal 
gland [18], and the kidney [19-21]. There are now a 
significant number of studies emerging in the literature, 
which report the presence of GABA and its receptors in 
renal tissue, with this in mind it is perhaps surprising 
that this well studied amino acid has not attracted more 
attention from renal physiologists. This review will 
summarise what is currently known about the 
expression and function of GABA, metabolic enzymes, 
and its receptors in the mammalian kidney and will 
seek to identify a potential role for a GABA system in 
the regulation of renal function. 
THE RENAL GABA SYSTEM 
Expression of GABA in the Kidney 
The rat is a commonly used model for the study of 
renal function and multiple studies now report a wide 
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distribution of GABA along the rat nephron [22-27]. 
Immunohistochemistry studies performed on rat kidney 
tissue report GABA immunoreactive structures in 
epithelial cells of the thin and thick ascending limbs of 
the loop of Henle, the connecting tubules, principal 
cells of the collecting duct [22, 28], the distal tubules 
[28] and the juxtamedullary cortex [23]. Such studies 
describe the densest expression of GABA to be in the 
inner stripe of the outer medulla [22], which is in 
contrast to earlier chromatography studies (performed 
on multiple mammalian species) which identify the 
renal cortex as having the greatest abundance of 
GABA [24]. As such there may be species-specific 
expression patterns for GABA. Interestingly, of the 
studies in which GABA expression in human renal 
tissue has been investigated, the highest concentration 
of GABA was also detected in the renal cortex, when 
investigating ‘healthy humans’ [24-26].  
Studies focusing on renal tubular acidosis provide 
evidence, which suggests detectable levels of GABA 
and GAD in the kidney are altered, although the reports 
regarding the effect this has on GABA synthesis are 
somewhat disparate. The GABA precursors glutamine 
and glutamic acid, are known to produce glucose and 
ammonia during renal gluconeogenesis and acidosis 
[27, 29, 30]. Spectroscopy studies utilising cortical 
tubules isolated from chronically acidotic rats report an 
increase in the rate of gluconeogenesis [30, 31] with a 
decrease in the rate of glutamine, aspartate and GABA 
formation [31]. Similarly, chromatography studies 
performed in rats report that chronic acidosis simulates 
a significant reduction in the concentration of GABA in 
rat kidney cortex, whereas levels of GABA in the brain 
were unaffected [24]. The underlying mechanisms are 
however controversial, in vivo studies in rats describe 
an increase in the level of renal GABA during acidosis, 
specifically in response to inhibition of GABA-T, which 
suggest the conversion of L-glutamic acid to GABA 
may be increased during ammoniagenesis. Thus, the 
function of the renal GABA pathway may be associated 
with ammoniagensis during acidosis [24]. Experiments 
performed on rat renal cortex tissue conversely 
suggest that the renal GABA pathway contributes to 
glutamate disposal and only plays a passive role in 
subsequent ammoniagenesis [32]. By contrast, other 
studies have reported that chronic acidosis in rats 
causes a significant increase in GAD activity in renal 
homogenates which would imply an increase in 
synthesis of GABA [33]. Conflicting chromatography 
data suggests GAD and GABA-T activity in the kidney 
remain unaltered by acidosis [24]. The disparate 
findings reported may simply be due to the differential 
experimental techniques employed, and further 
research is clearly needed. Currently, data from these 
preliminary studies suggest the renal GABA system is 
directly affected by chronic acidosis, and given the 
acidosis-associated loss of kidney function, the 
resulting impact this system might have on renal 
function may be significant in both health and disease. 
Expression of Metabolic Enzymes of GABA in the 
Kidney 
As is true for GABA, its metabolic partners have 
been detected in various locations throughout the 
nephron in a variety of different species (Table 1). 
Glutamic acid, the precursor to GABA, has been 
detected in proximal locations to GABA in the rat 
nephron, which include the epithelial cells of the thick 
portion of the loop of Henle in the outer medulla, the 
thin portion of the loop of Henle in the inner medulla, 
distal tubules, and principal cells of the collecting duct 
in both the inner and the outer medulla [20]. In addition, 
glutamic acid-specific immunoreactivity was also 
detected in areas of the nephron, in which GABA has 
not yet been identified, such as podocytes of the 
Bowman’s capsule [20].  
Previous studies performed in rats, have suggested 
that GABA can be synthesised intramurally in the 
kidney by multiple pathways. The majority of reports to 
date indicate GABA is synthesised from L-glutamic acid 
[24, 34, 35] via the intramitochondrial enzyme GAD, 
exclusively within tubules of the rat renal cortex [36], 
and that the renal GABA pathway accounts for 
approximately 25% of glutamic acid oxidation in the 
renal cortex [24]. Furthermore, one study suggests that 
the synthesis of GABA by decarboxylation of L-
glutamic acid in the rat renal cortex, might be different 
from the corresponding reaction in the brain [24], due 
to characteristic differences between renal GAD and 
brain GAD [26, 35], and renal GAD having two Km 
values [24]. A potential explanation for the differing Km 
values for renal GAD being that i) there is more than 
one form of GAD present within the kidney or ii) GAD 
binds differently at differing concentrations of the 
substrate [24].  
Notably, GABA has also been shown to be 
synthesised in vivo from putrescine, via an alternative 
biosynthetic pathway, in a range of peripheral tissues 
including the kidney [37, 38]. Putrescine is converted to 
GABA-aldehyde via diamine oxidase and is then 
converted to GABA via aldehyde dehydrogenase [39]. 
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Radioactivity studies performed in mouse kidney have 
shown that, following administration of [
14
C]-putrescine, 
significant amounts of radioactive carbon were 
recovered as GABA both in mouse kidney tissue and 
urine [38]. Future studies are needed to determine 
whether the two biosynthetic pathways operate 
simultaneously or whether they contribute differentially 
in space and time to GABA synthesis in the kidney. 
In addition, GAD activity has been detected in a 
range of peripheral tissues including the liver, oviduct, 
testis and the kidney [39, 40] (see Table 1). GAD 
activity reported in the kidney is second highest to that 
reported for the brain [40]. As mentioned above, renal 
GAD is distinct from GAD found in the brain due to its 
differential dependence on the cofactor pyridoxal 5’-
phosphate required for its enzymatic activity [35], 
sensitivity to antagonists and agonists, and sensitivity 
to dietary sodium. Unsurprisingly, when investigating 
the effect of dietary sodium on GAD activity, only renal 
GAD activity is reduced when rats were placed on a 
Table 1: The Location of GABA Receptor Subunits and GABA Metabolic Enzymes in the Kidney 
Components Nephron  Species mRNA vs. Protein References  
GABAAR Convoluted tubules 
Collecting duct 






























Whole kidney (m); renal cortex (r) (rb) 
Renal cortex (r) (rb); outer medulla (r); whole kidney (h)  
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Proximal and distal tubules (r); whole kidney (h) 
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Abbreviations: (h) refers to human, (r) refers to rat, (rb) refers to rabbit, and (m) refers to mouse. 
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low sodium diet [23]. Northern blot hybridisation 
experiments have shown that isolated cDNAs from rat 
and mouse brain libraries, encoding GAD65 and 
GAD67, do not hybridise to the RNA isolated from rat 
kidney [40, 41]. Functional studies in which GAD 
activity was assessed by measuring GABA 
radioactivity, report renal GAD is stabilised by ATP and 
NaCl (and in combination), whilst ATP inhibited brain 
GAD [42]. Conversely, radiometric assays performed 
on tissue from both rats and mice suggest that both 
kidney and brain derived GAD respond similarly to high 
concentrations of the inhibitor aminooxyacetic acid [32, 
43]. Regarding the specific location of active GAD, 
studies utilising rat renal cortex homogenates indicate 
GAD activity is three times greater within proximal 
tubules relative to the glomeruli [23]. Conflicting 
immunohistochemistry studies show GAD65 and 
GAD67 staining predominately in the glomeruli and 
arterioles in rats [21] and yet mRNA for GAD was not 
detected in glomeruli isolated from mice [44]. GAD65 
and GAD67 mRNA was however detected in the 
proximal and distal tubules in mice but not detected 
anywhere in the medulla [44]. In summary, data 
regarding the distribution and activity of GAD 
throughout the nephron, yielded from various studies, 
is somewhat disparate and evidence further speaks to 
the possibility of species differences in the importance 
of the GABA system in the kidney. In a disease 
context, GAD has been reported to be a major target 
for auto-antibodies generated in insulin-dependent 
diabetes mellitus [45] and as such the GAD expressed 
as an auto-antibody in renal tubules may contribute to 
diabetic tubulointerstitial disease. However, presently 
this is inconclusive and requires additional evidence for 
clarification [44]. 
In the CNS, GABA-T acts to catabolise GABA to 
succinate, in fitting with this established mechanism, 
quantification studies using rat kidney cortex 
homogenates have shown that GABA can be similarly 
catabolised by GABA-T to succinate [24]. Unlike renal 
GAD, renal GABA-T exhibits similar functional 
characteristics to neural GABA-T. Antibodies raised 
against mouse brain GABA-T have been shown to 
cross-react with renal GABA-T in the apical membrane 
of epithelial cells in the proximal and distal convoluted 
tubules [46]. Additionally studies performed on human 
kidney tissue, indicate neural and renal GABA-T both 
exhibit the necessity for the pyridoxal phosphate 
cofactor, respond similarly to specific inhibitors, have 
similar molecular weights, isoelectric pH, and substrate 
affinities [47]. Immunohistochemical studies have 
shown that GABA-T appears to be predominantly 
localised in the renal cortex of both rats [21, 32] and 
mice [46, 48] and more specifically is expressed in 
cortical proximal and distal tubules [46] and in 
medullary descending and ascending loops of Henle in 
mice [48]. Interestingly, others report its substrate 
GABA, is expressed predominately in the rat renal 
medulla [22]. The lack of correlation in expression of 
GABA and GABA-T might reflect the presence of 
differential enzymes and/or the presence of a unique 
GABA uptake mechanism in the medulla [22]. Its 
possible that, higher levels of GABA in the renal 
medulla, relative to the renal cortex, may coincide with 
a decreased catabolic rate of GABA in the medulla, 
although, this fails to equate with the dense cortical 
expression of GABAARs in both rats and mice 
(discussed below). 
In addition to the metabolic enzymes in the GABA 
shunt pathway, an active GABA uptake system also 
exists in the kidney, as it does in the CNS. 
Immunohistochemistry studies have detected the 
GABA transporter GAT2 on the basolateral side of 
cortical renal tubules in rats [21]. Functional studies 
performed on brush-border vesicles, derived from the 
proximal tubule luminal membrane, have shown active 
transport of GABA into the brush-border vesicles 
occurs in a sodium-dependent manner [49]. Authors of 
this study propose that high-affinity renal GABA 
transport might represent the need to maintain high 
intracellular levels of GABA in the intracellular space of 
rat renal cortical slices, or perhaps more importantly 
the need to minimise extracellular levels of GABA, 
which was also found in brush-border membrane 
vesicles [50]. The betaine/GABA transporter (BGT1), 
which has a higher affinity for GABA than betaine, has 
also been found in the renal medulla [51, 52] although 
studies to date have focused on its role in transporting 
the osmolyte betaine rather than establishing whether it 
contributes to the renal GABA system.  
Lastly it has been reported that the concentration of 
GABA in the urine is higher than that measured in the 
blood [12, 53], which begs the question as to whether 
GABA is released by the kidney to exert an extramural 





-ATPase inhibitor ouabain stimulates a 
significant increase in the efflux of endogenous GABA 
from slices of rat renal cortex and medulla [54]. These 
researchers propose that the depolarising stimulus-
evoked release of GABA from kidney tissue provides 
preliminary evidence favouring an extramural function 
for GABA [54]. 
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Localisation of GABAA Receptor Subunits in the 
Kidney 
Numerous studies now provide evidence for GABA 
receptor expression throughout the rat nephron. 
Radioreceptor binding studies and autoradiography 
studies performed in rats have identified binding sites 
for the GABAAR agonist muscimol in the convoluted 
tubules of the renal cortex, the collecting duct and the 
thick ascending limb of the loop of Henle [55]. These 
researchers confirmed that the binding sites were 
indeed conventional GABAA receptors by displacing 
(
3
H)-muscimol with muscimol, GABA, isoguvacine 
(GABAA receptor agonist) and bicuculline (GABAA 
receptor antagonist). Accumulating evidence shows 
that specific GABAAR subunits are present within the 
kidney in a range of species (see Table 1). 
Immunoprecipitation studies and 
36
Cl-uptake studies 
have identified a novel functional GABAAR within the 
proximal tubular cells of the rat kidney, co-assembled 
as 511 [56]. More recent studies having similarly 
detected 1 and 3 subunits in the renal cortex, have 
additionally detected  subunit mRNA and protein in 
Wistar-Kyoto rats [21]. Interestingly, GABAA  subunit 
mRNA levels are significantly reduced in 
spontaneously hypertensive rats (SHR) compared to 
wild-type rats on a normal salt diet, there was no 
significant differences reported on a high salt diet. 
Immunohistochemical observations indicate that the 1, 
3 and  subunits were mainly localised apically in 
cortical tubules, whereas immunoblot experiments 
reveal a potential novel combination of these GABAA 
receptor subunits in the kidney [21]. Interestingly, 
opposing evidence exists for the specific renal 
expression of the 5, 1, 2, 3, 1 and 2 subunits of 
GABAA receptors [21, 56], this may again be due to the 
different PCR techniques or the different rat strains 
used in these two studies. 
Studies in mice have detected mRNA expression of 
GABAAR 2, 6, 2, 2, 3 subunits in the renal system. 
Western blot experiments reveal a greater expression 
of GABAAR protein in the mouse medulla than mouse 
cortex [57]. Currently, it is unclear as to whether the 
amount of GABA in the mouse medulla compliments 
the expression of GABAAR protein. Collectively, data 
suggest that different forms of GABAARs, are located 
along the rat nephron in different species, which likely 
consist of different subunit combinations, thereby 
exerting different pharmacological characteristics. To 
fully appreciate the potential signalling functions of the 
renal GABA system, future studies must first establish 
the different subunit compositions of GABAARs located 
throughout the kidney. 
It is well established that GABAARs are modulated 
by benzodiazepines [58-61] and it has been suggested 
that peripheral benzodiazepine receptors (PBR), 
unrelated to GABAARs, also activated by 
benzodiazepines, are present in the kidney. Studies 
propose variations in benzodiazepine binding to PBRs 
in the kidney following acute angiotensin II infusion 
[62], in SHR models [63-65], and after angiotensin II-
induced hypertension [66]. Moreover, more recent 
studies report selective PBR agonists are protective 
against ischemic renal injury in rats [67]. Interestingly 
the potential for renal GABA and GABAARs, or their 
potential renoprotective role is not investigated in this 
study and yet given the accumulating evidence for a 
functional GABA system in the kidney it certainly 
seems feasible that GABAARs might be involved in the 
reported PBR agonist-evoked protection against 
ischemic renal injury. 
Unlike GABAARs, very little is known about 
GABABRs in the kidney. Autoradiographic studies have 
detected binding sites for the GABABR agonist 
baclofen, indicating a potential presence of GABABRs 
in the kidney. These binding sites were exclusively 
detected in the rat renal cortex and absent from the 
medulla [68]. Specifically, GABABR R1 and R2 subunits 
have been detected at both the mRNA and protein 
level in the rat renal cortex [21], the R1 subunit being 
detected in the glomeruli, arterioles and renal tubules, 
and R2 subunit detected in the proximal-like tubules 
and collecting duct-like tubules [21]. Contrary to 
detection of GABAAR subunits in the proximal tubules 
[55, 56, 69], the detection of GABABRs within the renal 
cortex and the dense expression of GAD in the 
proximal tubules in rats [23], electron microscopy 
studies failed to detect GABA immunoreactive 
structures in both the renal corpuscles and proximal 
convoluted tubules in rats [22]. Future studies are 
required to reconcile expression of both types of GABA 
receptors with GABA and its metabolic enzymes in rat 
kidneys. 
The Function of GABA in the Kidney 
In light of the evidence for the presence of GABA, 
its metabolic enzymes and both GABAA and GABAB 
receptors in the kidney of a range of mammalian 
species, including humans [21, 56] it seems plausible 
that there is a physiologically relevant role, or roles, for 
the renal GABA system.  
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Antihypertensive Role of GABA 
There is increasing evidence that suggests GABA is 
able to modulate renal functions, such as urine 
formation, blood flow and sympathetic neurotransmitter 
release. Experiments performed using isolated 
perfused rat kidney indicate that GABA may modulate 
urine formation, by stimulating an increase in the 
fractional excretion of water, sodium and glucose, 
presumably by acting on GABABR to induce 
vasoconstriction at the afferent arteriole [70]. In support 
of this, a more recent study showed that in vivo 
administration of baclofen, induced diuresis, natriuresis 
kaliuresis and increased glucose exaction in 
anaesthetised rats [71]. Alternative data collected from 
isolated perfused rat kidney studies, demonstrate 
GABA-mediated suppression of renal nerve 
stimulation, due to attenuation of noradrenaline release 
and vasoconstriction, as a result of the activation of 
presynaptic GABABRs [72]. This suppressive effect of 
GABA on noradrenaline release has also been 
reported in SHR, when GABA was perfused via the 
mesenteric artery [73]. Analogous to GABA, perfusion 
with baclofen inhibits perivascular nerve stimulation-
induced increases in perfusion pressure and 
noradrenaline release in the mesenteric arterial bed 
[73], and isolated perfused rat kidney [72]. 
In addition to this suppressive effect on sympathetic 
nerve activity, GABA has been shown to have 
antihypertensive properties. Interestingly, both 
intracerebroventricular (ICV) injections [74] and oral 
administration [75] of GABA reduced blood pressure in 
SHR [73] and to a lesser extent in normotensive rats 
[74]. ICV injections of GABA also caused a significant 
reduction in heart rate in SHR and to a lesser extent in 
normotensive rats, an observation that was not 
recapitulated when GABA was administered orally. 
Microinjections of baclofen, into the paraventricular 
nucleus of the hypothalamus caused a similar 
reduction in arterial blood pressure in SHR to that 
observed in response to GABA [75]. Also, ICV 
injections of muscimol, caused a decrease in mean 
arterial blood pressure in stroke-prone SHR [76] and in 
anesthetised cats [77-79]. GABA and muscimol have 
been shown to cause a reduction in blood pressure, 
heart rate and renal nerve discharge more effectively 
when administered by an ICV injection relative to an 
intravenous injection [77, 79]. This effect was reversed 
by intravenous administration of bicuculline [77-79]. 
This implies that the hypotensive effect of GABA and 
muscimol in anesthetised cats is mediated by CNS 
stimulation rather than acting on a peripheral site of 
action. A later study showed that pretreatment with 
sarthran, an angiotensin receptor antagonist, reduced 
the hypotensive effect of GABA and the hypertensive 
effect of bicuculline in SHR and normotensive rats [80] 
implying that the hypotensive effect of GABA is 
mediated via the angiotensin system in the CNS. The 
above evidence suggests that the effect of GABA on 
reducing blood pressure, heart rate and sympathetic 
nerve responses is consistent in all species studied to 
date. Depending on the manner in which GABA was 
administered, and the specific location within the body, 
the antihypertensive effect was mediated either through 
GABAARs or GABABRs. In extension, overexpression 
of the GABABR1 gene in the brain, specifically the 
nucleus of the solitary tract, results in an increase in 
blood pressure and heart rate in normotensive rats 
[81]. This adds credibility to the notion that the 
GABAergic system plays an essential role in regulating 
blood pressure in the brain. It should be the subject of 
future research to determine if the antihypertensive 
effect of GABA, or analogues with similar properties, 
will have any therapeutic advantages to humans.  
Renoprotective Role of GABA 
In addition to the antihypertensive role of GABA in 
the kidney, a renoprotective role in acute renal failure in 
rats has been indicated. The enhancement of renal 
sympathetic nerve activity and noradrenaline overflow 
are paramount to the progression of ischemia/ 
reperfusion induced renal injury. Oral administration of 
GABA in rats, attenuates the physiological changes 
associated with glycerol-induced acute renal failure 
including, an increase in body weight, kidney weight, 
blood urea and creatinine [82]. More recent studies 
have shown that intravenous treatment with GABA or 
intravenous treatment with baclofen, attenuates the 
enhanced renal sympathetic nerve activity and the 
associated increase in noradrenaline overflow known to 
occur in ischemic acute kidney injury in rats [83]. Thus, 
the suppressive role of GABA on the enhanced nerve 
activity, seemingly via GABABRs, serves to suppress 
renal dysfunction, which may be therapeutically 
relevant in treating acute renal failure in humans. In 
support of the relevance of the renoprotective role of 
GABA in a clinical setting, GABA also elicits a 
protective role against cisplatin-induced acute kidney 
injury in rats [84]. Takano et al. (2014) proposed that 
since over stimulation of renal sympathetic nerve 
activity is associated with the renin-angiotensin-
aldosterone system, activation of GABABRs in the 
distal-like tubules might alter this system [21]. 
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Figure 1: DIC imaging of GABA-evoked pericyte-mediated constriction of in situ vasa recta capillaries. (Ai-iii) Images of 
vasa recta capillaries are taken from a time series experiment in which kidney slices were exposed to GABA (3 μM). Vessel 
diameter was measured every 5 s throughout the course of the experiment at the pericyte site (red dashed lines) and the 
corresponding non-pericyte site (green dashed lines) of the same vasa recta. (Ai-iii) Yellow dotted circles denote the pericyte. 
(Ai) A typical field of view of vasa recta superfused with PSS under control conditions. (Aii) Application of GABA (3 μM) caused 
a reduction in vasa recta diameter at the pericyte site. (Aiii) Following the removal of GABA from the perfusate, a further 
reduction in vasa recta diameter at the pericyte site occurs. (B) Depicts a representative trace of percentage change in vasa 
recta diameter at pericyte site (black trace) and non-pericyte site (grey trace) over time in response to GABA (3 μM) exposure. 
(C) Mean data showing percentage change in vessel diameter at pericyte sites (black bar) and non-pericyte sites (grey bar) 
during the presence of GABA (3 μM). GABA-evoked a significantly greater vasoconstriction of vasa recta at pericyte sites 
relative to non-pericyte sites. Values are mean SEM, * P<0.001, n = 12. 
Additional evidence favouring a protective role for 
GABA in the kidney has been demonstrated following 
oral administration of GABA in nephrectomised rats, 
the effect of GABA being attenuation of fibrosis and 
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atrophy, primarily in renal tubules. Specifically, GABA 
resulted in a reduction in renal functional losses as 
determined by measuring creatinine, serum urea 
nitrogen, urinary protein levels, and the increased 
expression of TGF- 1 and fibronectin in renal tubules 
[85]. Conversely, GABA failed to exert significant 
protective effects in the glomeruli. Selective GABAAR 
and GABABR agonists reproduced the GABA-mediated 
amelioration of renal functions, suggesting a role for 
both GABAARs and GABABRs in improved outcomes in 
nephrectomised rats. Interestingly, expressions of both 
GABAARs and GABABRs in proximal tubules were 
decreased in nephrorectomised rats, which was later 
increased following GABA administration [85]. These 
preliminary results imply that oral administration of 
GABA might offer beneficial outcomes such as 
reducing fibrosis and attenuating renal dysfunction, 
when used in conjunction with other medication, to 
treat renal failure.  
Regulation of Blood Flow by GABA 
Beyond its role as a neurotransmitter in the CNS, 
some studies have shown that GABA can regulate 
blood flow. For instance, the uptake of GABA into 
astrocytes has been shown to stimulate 
vasoconstriction of blood vessels, within the nerve 
layer of the olfactory bulb, which was attenuated by the 
inhibition of GABA uptake by an mGAT4 inhibitor, 
SNAP 5114, in mice [86]. Other studies have shown 
that GABA can serve as a vasodilator via its action on 
vascular smooth muscle cells surrounding blood 
vessels in different regions of the brain in dogs [87], 
rats [88], and rabbits [89]. 
Contractile pericytes are known to regulate capillary 
diameter in a similar way to their counterpart vascular 
smooth muscle cells that surround larger vessels [90-
98]. In whole mount retinae, application of GABA 
receptor blockers caused pericyte-mediated 
vasoconstriction; implying endogenous GABA may act 
as a tonic vasodilator in the retina. Pericytes are 
expressed throughout all mammalian tissues and 
organs including the kidney and recent studies have 
highlighted the importance of renal pericytes in 
regulating medullary blood flow and the associated 
maintenance of the cortico-medullary gradient required 
for appropriate urine concentration [99]. Given that 
GABA is known to induce vasoconstriction in the 
afferent arteriole in the rat kidney [70] and may act to 
tonically regulate capillary diameter via pericytes in the 
retina [96], we examined whether GABA acted at vasa 
recta pericytes in the renal medulla to alter capillary 
diameter and blood flow in this region. Using a live 
kidney slice model [98], we have demonstrated that 
GABA causes pericyte-mediated vasoconstriction of 
vasa recta (Figure 1). These data describe a novel role 
for GABA in pericyte-mediated regulation of medullary 
blood flow (MBF).  
CONCLUSION 
Although the expression of the renal GABA system 
has been explored for several decades, the precise 
function, and importance, of this system within the 
kidney remains obscure. More recent progress has 
established GABA as having both an antihypertensive 
and renoprotective role within the kidney, although the 
precise mechanism(s) remain undetermined at present. 
Further investigations are needed to establish the 
physiological relevance of these GABA-mediated 
effects and whether there is a therapeutic potential for 
these findings in humans. In light of the research 
discussed, it is evident that GABA can be synthesised 
within the kidney and it is also present within blood and 
urine. Future studies focusing on defining the function 
of the renal GABA system may help identify if it can be 
used as therapeutic targets for treatment of kidney 
diseases. As to the role of GABA as a modulator of 
MBF via its action at vasa recta pericytes, further 
investigations are underway in our laboratory. It is 
apparent that a role for GABA in non-neural tissues is 
emerging and more research is needed to provide 
greater insight in the significance of the renal GABA 
system.  
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